IL18 and bacterial infectious disease: In addition, treating C57BL/6 mice with a dosage of αIL-22 prior to bacterial infection not only reduced the mucus thickening seen in infected mice given the IgG control (Fig S2A) but also abrogated the infection-induced release of IL-22 from the cecum (Fig S2B), and decreased IL-18 production in comparison to control IgG-treated mice (Fig S2C).